We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

CT-Based Radiomics Deep Learning Predicts Lymph Node Metastasis in Tumors

By MedImaging International staff writers
Posted on 24 Jan 2024
Print article
Image: The AI model has demonstrated an 89% success rate in predicting lymph node metastasis (Photo courtesy of 123RF)
Image: The AI model has demonstrated an 89% success rate in predicting lymph node metastasis (Photo courtesy of 123RF)

Nonfunctional pancreatic neuroendocrine tumors, although uncommon, are primarily managed through surgical intervention. The decision-making process for surgery and other treatments is heavily influenced by the presence or absence of lymph node metastasis. There is currently a lack of consensus in clinical guidelines, especially regarding the necessity of surgery for tumors less than 2 cm in size. The preoperative diagnosis of lymph node metastasis through existing methods is not sufficiently reliable. To address this, researchers have now introduced an imaging model that combines radiomics (the extraction of data from radiological images) and deep learning to predict preoperative lymph node metastasis in these tumors. This innovative model marks a significant step forward in the non-invasive assessment of lymph node metastasis, facilitating more precise diagnosis and aiding in the determination of the most effective treatment strategies.

The team at the University of Tsukuba (Tsukuba, Japan) developed this predictive model by integrating radiomics features obtained from CT and MRI scans with advanced artificial intelligence deep-learning techniques. Impressively, this model exhibited an 89% accuracy rate in predicting lymph node metastasis, which further increases to 91% when validated with data from an external hospital. Remarkably, its performance remains stable regardless of whether the tumor size is above or below 2 cm. This model thus serves as a vital tool for predicting lymph node metastasis, equipping surgeons with essential information to select the most suitable surgical interventions and treatment plans. The development holds the potential to significantly improve patient outcomes in this challenging medical field.

Related Links:
University of Tsukuba

Gold Member
Ultrasound System
FUTUS LE
Gold Member
Electrode Solution and Skin Prep
Signaspray
Mobile Imaging Table
medifa 8000 hybrid
Double Sided Apron
Maxima

Print article
Radcal

Channels

MRI

view channel
Image: PET/MRI can accurately classify prostate cancer patients (Photo courtesy of 123RF)

PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients

The Prostate Imaging Reporting and Data System (PI-RADS) is a five-point scale to assess potential prostate cancer in MR images. PI-RADS category 3 which offers an unclear suggestion of clinically significant... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more